1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,330 | 1,390 | 05.08. | |
| 1,330 | 1,390 | 05.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides | 402 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 23.07. | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | 587 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 21.07. | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 660 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 16.07. | WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | 620 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 14.07. | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 721 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 01.07. | NanoViricides: There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | 491 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.06. | With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | 521 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the... ► Artikel lesen | |
| 04.06. | NanoViricides Measles Drug Development Animal Study is Imminent | 597 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 28.05. | NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | 888 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 22.05. | The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan | 768 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.The... ► Artikel lesen | |
| 16.05. | NanoViricides GAAP EPS of -$0.14 | 7 | Seeking Alpha | ||
| 16.05. | NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu | 831 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025... ► Artikel lesen | |
| 15.05. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | 829 | ACCESS Newswire | NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC)... ► Artikel lesen | |
| 08.05. | NanoViricides: Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo | 826 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES)... ► Artikel lesen | |
| 05.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC | 826 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 29.04. | Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It | 690 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 14.04. | Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak | 926 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 11.03. | NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company | 1.123 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that... ► Artikel lesen | |
| 04.03. | Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan | 1.022 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 25,400 | -5,22 % | EQS-News: Formycon AG: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 3. Quartal 2025 bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen... ► Artikel lesen | |
| SOLESENCE | 2,925 | +16,30 % | Solésence, Inc.: Solésence Reports Second Quarter 2025 Financial Results | ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced... ► Artikel lesen | |
| ONTO INNOVATION | 83,00 | -1,19 % | EQS-Media: LPKF Laser & Electronics SE: Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran | EQS-Media / 02.04.2025 / 09:00 CET/CEST
Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran
LPKF schließt sich dem Packaging Applications... ► Artikel lesen | |
| KOPIN | 1,771 | +12,23 % | Auftrag von Lockheed Martin treibt Kopin-Aktie an | ||
| GOMSPACE | 1,112 | -2,46 % | GOMSPACE GROUP AB: The Hargreaves Family No. 14 Settlement receives FDI-approvals in relation to the directed issue of new shares of SEK 196 million and the directed share issue has thus been completed | ||
| OBDUCAT | 0,030 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| GAUZY | 6,570 | +2,18 % | GAUZY LTD: Gauzy Announces Minimal to No Impact on Business with Its U.S. Customers Amid United States New Tariff Policy on Imports | Gauzy's Long-Established 20,000 SqFt Production Facility in Florida, Originally Designated to Support U.S. Aeronautics Customers, Already Serves All Company Divisions, Including Architecture, Automotive... ► Artikel lesen | |
| VEECO INSTRUMENTS | 17,100 | -4,47 % | University of Michigan synthesizes high-quality 2D molybdenum disulfide using Veeco's Fiji ALD system | ||
| FENDX TECHNOLOGIES | 0,040 | -17,15 % | FendX Technologies Inc.: FendX Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company using... ► Artikel lesen | |
| ZENTEK | 0,710 | +2,90 % | Zentek Ltd.: Zentek Announces Management Transition | GUELPH, ON / ACCESS Newswire / July 11, 2025 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company, announces... ► Artikel lesen | |
| DOTZ NANO | 0,023 | +4,55 % | DOTZ NANO LIMITED: Cleansing Notice | ||
| ACACIA RESEARCH | 2,980 | +3,47 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| NVE | 52,00 | 0,00 % | Dividendenbekanntmachungen (04.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERIPRISE FINANCIAL INC US03076C1062 1,6 USD 1,3806 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,0258 EUR ATLANTIC UNION... ► Artikel lesen | |
| LAMPETIA | 0,076 | -32,14 % | EQS-News: LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Jahresergebnis
LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis
30.06.2025 / 16:18 CET/CEST
Für den... ► Artikel lesen | |
| NANOFOCUS | 1,120 | 0,00 % | NanoFocus: Hauptaktionär plant Squeeze-out | Die Carl Mahr Holding GmbH hat ein offizielles Verlangen auf Durchführung eines aktienrechtlichen Squeeze-outs bei der NanoFocus AG übermittelt. Demnach soll die Hauptversammlung einen Beschluss fassen... ► Artikel lesen |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,16 % bei einem Aktienkurs von 1,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.